Interstitial keratitis before treatment with well-circumscribed avascular opacities at varying stromal depths (A), and a slitbeam showing stromal opacity (B).
Improved interstitial keratitis following corticosteroid treatment.
Nagpal A, Vora R, Margolis TP, Acharya NR. Interstitial Keratitis Following Varicella Vaccination. Arch Ophthalmol. 2009;127(2):222-229. doi:10.1001/archophthalmol.2008.569
Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2009
Varicella is a highly transmissible disease caused by the varicella-zoster virus, with the most common manifestations being a maculopapular and/or vesicular rash accompanied by a fever. Current vaccination recommendations by the Advisory Committee on Immunization Practices include the administration of a vaccine for the prevention of varicella in children.1 Rare cases of ocular disease (sclerokeratouveitis and anterior uveitis) following varicella vaccination have been reported in the literature, associated with both the live attenuated Oka strain used in the vaccine and the wild-type virus.2,3 We report a case of avascular interstitial keratitis following the administration of the varicella vaccine. To our knowledge, this complication of the Oka strain vaccine has not been previously reported.
An 11-year-old girl was referred for new-onset blurry vision in the right eye 2 weeks after being vaccinated with the Oka strain of the varicella-zoster virus (Varivax; Merck and Co, Inc, Whitehouse Station, New Jersey). A standard dose of 0.5 mL was injected into the left deltoid without any resulting skin reaction. Her medical history was significant for mild eczema and a seizure disorder treated with daily oral levetiracetam, and results of an ocular examination 1 year prior were normal. One week following the administration of the vaccine, she developed rhinitis and a mild fever that lasted 2 days. Two weeks following the vaccination, she noted blurry vision and photophobia in the right eye and her mother noted 3 white spots on the cornea. On examination, visual acuity measured 20/30 OD and 20/20 OS. Corneal sensation was normal in both eyes. Intraocular pressure measured 14 mm Hg OD and 18 mm Hg OS. There was no conjunctival injection or anterior chamber inflammation. In the right cornea, there were several well-circumscribed avascular opacities that appeared to be white blood cells at varying stromal depths (Figure 1). The left eye was unaffected. The posterior segment examination results were normal in both eyes. Epstein-Barr virus DNA was not detected by polymerase chain reaction. The patient was treated with a 1-month course of prednisolone acetate, 1%, starting at 4 times per day, with resolution of the interstitial keratitis at 2 weeks and return of visual acuity to 20/20 OD (Figure 2). At the 6-month follow-up visit, there was no sign of recurrence.
Complications of the Varivax vaccine have included disease caused by both wild-type and Oka strain varicella-zoster virus. There are few reports of ocular manifestations after varicella vaccination in the literature, and we found no previous reports describing avascular interstitial keratitis. In the case that we have reported, the close temporal association of the vaccination and the development of a corticosteroid-responsive keratitis lead us to suggest that this complication represented an immune-mediated response to the vaccine strain. One possible explanation for the unilaterality is that she rubbed 1 eye with a hand that had previously touched her site of inoculation, leading to unilateral antigen presentation to the cornea and unilateral disease. Unilateral disease has frequently been described following smallpox vaccination, presumably from this type of touch.4 In addition, systemic diseases may also manifest unilaterally. Immune-mediated interstitial keratitis should be recognized as a possible adverse effect of the varicella vaccine.
Correspondence: Dr Acharya, Francis I. Proctor Foundation for Research in Ophthalmology, University of California, San Francisco, 95 Kirkham St, San Francisco, CA 94143-0944 (email@example.com).
Author Contributions: Dr Acharya had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Financial Disclosure: None reported.
Funding/Support: This work was supported by grant EY06190 from the National Eye Institute and an unrestricted grant from Research to Prevent Blindness. Dr Acharya is supported by grant K23EY017897 from the National Eye Institute and a Research to Prevent Blindness Career Development Award.
Role of the Sponsors: The sponsors had no role in the design or conduct of the study, data analysis, or manuscript preparation.